Effects of Simvastatin on Biomarkers
Completed · Phase 4 · Has a placebo group
Conditions studied: Alzheimer's Disease
In brief
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
Key facts
- Study ID
- NCT01142336
- Run by
- University of Washington
- People needed
- 49
- Starts
- 2010-06-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2017-07-28
Who can join
Age: 45 and older, up to 64. Sex: any. Healthy volunteers: accepted.
Where it is running
- VA Puget Sound Health Care System — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.